1. Academic Validation
  2. Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4

Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4

  • Bioorg Med Chem. 2013 Mar 1;21(5):1357-66. doi: 10.1016/j.bmc.2012.11.056.
Nancy Ty 1 Renée Pontikis Guy G Chabot Emmanuelle Devillers Lionel Quentin Stéphane Bourg Jean-Claude Florent
Affiliations

Affiliation

  • 1 Institut Curie, Centre de Recherche, 26 rue d'Ulm, Paris F-75248 Cedex 05, France.
Abstract

To evaluate the influence of stereochemistry on biological activities of cis-cyclopropyl combretastatin A4 (CA4) analogues, we have prepared several cyclopropyl compounds in their pure enantiomeric forms. The key reactions in our synthesis are the cyclopropanation of a (Z)-alkenylboron compound bearing a chiral auxiliary, and the cross-coupling of both enantiomeric cyclopropyl trifluoroborate salts with aryl and olefinic halides. Three pairs of cis-cyclopropyl CA4 analogues were evaluated for their potential antivascular activities. The diarylcyclopropyl compounds with SR-configuration (-)-1b, (-)-2b and the cyclopropylvinyl enantiomer (+)-3a with RR-configuration were the most potent tubulin polymerization inhibitors. A correlation was noted between anti-tubulin activity and rounding up activity of endothelial cells. The cytotoxic activity on B16 melanoma cells was in the submicromolar range for most compounds, but unlike the anti-tubulin activity, there was no difference in cytotoxic activity between racemic and enantiomerically pure forms for the three series of compounds. Molecular docking studies within the colchicine binding site of tubulin were in good agreement with the tubulin polymerization inhibitory data and confirmed the importance of the configuration of the synthesized cis-cyclopropyl CA4 analogues for potential antivascular activities.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》